TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
TriSalus Life Sciences Inc TLSI
$4.54
▼ -0.44%
($-0.02)
📅 Earnings This Week
Open
$4.55
Prev Close
$4.56
Day Range
$4.38 – $4.59
52W Range
$2.20 – $7.95
Market Cap
$278.83M
Beta
0.40
EPS (TTM)
$-0.68
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-12-18 |
| Shares Out. | 61,420,000 |
| Website | trisaluslifesci.com/ ↗ |
| Phone | 13026365400 |
| Employees | 102 |
| Revenue | $8.9M |
| Gross Profit | $7.7M |
| Net Income | $1.5M |
| Free Cash Flow | -$20.3M |
| Total Assets | $71.0M |
| Total Liabilities | $58.2M |
| Equity | $12.8M |
About TriSalus Life Sciences Inc
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
TriSalus Life Sciences Inc is a publicly traded company under the ticker symbol TLSI on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-07-01)